| Previous close | 116.95 |
| Open | 117.50 |
| Bid | 115.95 x 27700 |
| Ask | 115.95 x 21000 |
| Day's range | 116.20 - 117.60 |
| 52-week range | 65.70 - 151.00 |
| Volume | 5 |
| Avg. volume | 1,435 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
DGAP-News: MorphoSys AG / Key word(s): Conference 02.06.2020 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, June 2, 2020MorphoSys to Present at Upcoming Virtual Investor Conferences MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will present at the following virtual conferences:Jefferies Healthcare Conference Date: June 3, 2020, 9:30am EDT (3:30pm CEST, 2:30pm BST) Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, Dr. Julia Neugebauer, Director Corporate Communications & IRGoldman Sachs 41st Annual Global Healthcare Conference Date: June 10, 2020, 8:50am EDT (2:50pm CEST, 1:50pm BST) Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, Dr. Julia Neugebauer, Director Corporate Communications & IRJ.P. Morgan European Healthcare Conference Date: June 18, 2020 Presenter: Jens Holstein, Chief Financial Officer of MorphoSys, Dr. Julia Neugebauer, Director Corporate Communications & IRJMP Hematology and Oncology Forum Date: June 18, 2020 Presenter: Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, Dr. Julia Neugebauer, Director Corporate Communications & IRPDF versions of the presentations will be provided at www.morphosys.com. Links to available webcasts will be filed under www.morphosys.com/conference-calls. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc. For more information, please contact: MorphoSysInvestor Contact: Dr. Julia Neugebauer Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-179 Julia.Neugebauer@morphosys.com Media Contacts: Dr. Anca Alexandru Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26738 Anca.Alexandru@morphosys.com Dr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 Verena.Kupas@morphosys.com * * *Additional features: File: Media Release * * *02.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1061279 End of News DGAP News Service
DGAP-News: MorphoSys AG / Key word(s): AGM/EGM 27.05.2020 / 19:06 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, May 27, 2020MorphoSys AG Reports Outcome of Annual General Meeting 2020All Proposed Resolutions Approved MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company's Management and Supervisory Boards at the Company's virtual Annual General Meeting which took place on Wednesday, May 27, 2020, including: * The discharge of the members of the Management and Supervisory Boards with respect to the 2019 financial year * The appointment of PricewaterhouseCoopers AG as auditor for the 2020 financial year * Resolution on the reduction of the number of Supervisory Board members * Resolution on the election of Supervisory Board members * Resolution on an amendment to the Articles of Association with regard to the prerequisites for participation in the Annual General Meeting * Resolution on an amendment to the Articles of Association with regard to conducting the Annual General Meeting * Resolution on the adjustment of the Supervisory Board remuneration * Resolution on the cancellation of Authorized Capital 2017-I and the creation of new Authorized Capital 2020-I with the option to exclude statutory subscription rights * Resolution on the creation of Conditional Capital 2020-I and the authorization to grant subscription rights to members of the Management Board of MorphoSys AG, members of the executive management bodies of affiliated companies in Germany and abroad and selected employees of MorphoSys AG and affiliated companies in Germany and abroad (Stock Option Plan 2020)At the 2020 virtual Annual General Meeting of MorphoSys AG, 60.28 % of the current share capital were represented. The Company made use of the option provided by the German legislator in view of the coronavirus pandemic to conduct ordinary annual general meetings in 2020 without the physical presence of shareholders or their proxies. Via a password-protected web service, registered shareholders could, among other things, visually and audibly follow the entire Annual General Meeting, exercise their voting rights and submit questions.Effective April 11, 2020, Supervisory Board member Dr. Frank Morich resigned from the Supervisory Board of MorphoSys AG at his own request. He had been appointed to the Supervisory Board in May 2015. By resolution of today's Annual General Meeting, the size of the Supervisory Board was reduced to six members."On behalf of my colleagues of the Supervisory Board I would like to thank Dr. Frank Morich for his commitment and invaluable support over many years and wish him every success in the future," said Marc Cluzel, M.D., Chairman of the Supervisory Board of MorphoSys AG."I would like to thank our shareholders for their continued support and trust, also on behalf of my colleagues on the Management Board," commented Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys AG.More information on the Company's Annual General Meeting including the voting results on all agenda items can be found at www.morphosys.com/agm. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc. MorphoSys forward looking statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact: MorphoSysInvestor Contact: Dr. Julia Neugebauer Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-179 Julia.Neugebauer@morphosys.com Media Contacts: Dr. Anca Alexandru Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26738 Anca.Alexandru@morphosys.com Dr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 Verena.Kupas@morphosys.com * * *Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=APFGJXJWRC Document title: Media Release * * *27.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1056677 End of News DGAP News Service
DGAP-News: MorphoSys AG / Key word(s): Regulatory Admission 20.05.2020 / 20:00 The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, May 20, 2020MorphoSys and Incyte Announce the Validation of the European Marketing Authorization Application for Tafasitamab\- The MAA seeks approval of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the validation of the European Marketing Authorization Application (MAA) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), including DLBCL arising from low grade lymphoma, who are not candidates for autologous stem cell transplantation (ASCT). The validation of the MAA by the European Medicines Agency (EMA) confirms that the submission is ready to enter the formal review process."The EMA's validation of the MAA for tafasitamab is a critical step on the path to making tafasitamab available for use in combination with lenalidomide in eligible patients with r/r DLBCL in Europe," said Peter Langmuir, M.D., Group Vice President, Targeted Therapeutics, Incyte. "We will continue to work closely with the EMA to progress the review of this application, with the hope of bringing this novel therapy to eligible patients as soon as possible.""We are pleased to have achieved this important milestone, which moves tafasitamab in combination with lenalidomide into the formal regulatory review process in the European Union," said Dr. Malte Peters, Chief Research & Development Officer, MorphoSys. "Following the U.S. FDA's acceptance of our Biologics License Application filing for tafasitamab for Priority Review earlier this year, this represents another major step forward. We look forward to continuing to work with the regulatory authorities alongside our partners at Incyte to bring this novel therapeutic option to eligible patients in need."The MAA, submitted by MorphoSys, is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with r/r DLBCL; and is supported by the Re-MIND study, an observational retrospective study in r/r DLBCL. If approved, Incyte will hold the marketing authorization, and has exclusive commercialization rights for tafasitamab outside of the United States, including Europe.DLBCL is the most common type of non-Hodgkin lymphoma in adults worldwide - comprising 40% of all cases1. It is an aggressive disease affecting the B-cells of the immune system with 30-40% of patients who do not respond to initial therapy or relapse thereafter, leading to a high medical need for new, effective therapies2.About L-MIND The L-MIND trial is a single arm, open-label Phase 2 study (NCT02399085) investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Two-year data, assessed by an independent review committee (November 30, 2019 cut-off), evaluating 80 patients receiving tafasitamab and lenalidomide corroborate previously reported primary analysis data. For more information about L-MIND, visit https://clinicaltrials.gov/ct2/show/NCT02399085. About Re-MIND Re-MIND, an observational retrospective study (NCT04150328), was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys' L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND was met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy. For more information about Re-MIND, visit https://clinicaltrials.gov/ct2/show/NCT04150328. About Tafasitamab Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing.In January 2020, MorphoSys and Incyte entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. If approved, MorphoSys and Incyte will co-commercialize tafasitamab in the United States. Incyte has exclusive commercialization rights outside the United States.Tafasitamab is being studied as a therapeutic option in B-cell malignancies in a number of ongoing combination trials, including L-MIND and Re-MIND, as well as the ongoing Phase 3 B-MIND study evaluating the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax. XmAb(R) is a trademark of Xencor, Inc.About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. About MorphoSys MorphoSys is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 28 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has over 400 employees. More information at www.morphosys.com. Incyte Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether tafasitamab will be approved for use in humans anywhere in Europe, the U.S. or elsewhere or will be commercialized in Europe, the U.S. or elsewhere successfully or at all; whether tafasitamab will be effective in the treatment of the indications discussed in this press release; and the expectations, timing and potential results of further development activities involving tafasitamab. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining regulatory approval for this planned collaboration; research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors, including other scientific developments; unanticipated delays; the effects of market competition; risks associated with relationships between collaboration partners; the impact of governmental actions regarding pricing, importation and reimbursement for pharmaceuticals; and such other risks detailed from time to time in each company's reports filed with the Securities and Exchange Commission, including Incyte's annual report on Form 10-Q for the quarter ending March 31, 2020 and MorphoSys' Annual Report on Form 20-F for the fiscal year ended December 31, 2019. Each party disclaims any intent or obligation to update these forward-looking statements. MorphoSys Forward-looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreements for tafasitamab, the further clinical development of Tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.References1\. Sarkozy C, et al. Management of relapsed/refractory DLBCL. Best Practice Research & Clinical Haematology. 2018 31:209-16. doi.org/10.1016/j.beha.2018.07.014.2\. Skrabek P, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Current Oncology. 2019 26(4): 253-265. doi.org/10.3747/co.26.5421. For more information, please contact: IncyteMedia Contacts:Catalina Loveman Executive Director, Public Affairs Tel: +1 302 498 6171 cloveman@incyte.comEla Zawislak Director, Public Affairs Tel: + 41 21 343 3113 ezawislak@incyte.comInvestor Contact:Dr. Michael Booth Division VP, IR & Global Responsibility Tel.: +1 302 498 5914 mbooth@incyte.comMorphoSysMedia Contacts: Dr. Anca Alexandru Associate Director, Corporate & IR Tel: +49 (0) 89 / 899 27-26738 anca.alexandru@morphosys.comDr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 verena.kupas@morphosys.com Investor Contact:Dr. Julia Neugebauer Director Corporate Communications & IR Tel.: +49 (0) 89 / 899 27-179 julia.neugebauer@morphosys.com* * *Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=CPKUEVJDTM Document title: Media Release * * *20.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1052381 End of News DGAP News Service
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 14.05.2020 / 17:36 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, May 14, 2020 MorphoSys to Present Data on Tafasitamab at the ASCO and EHA Virtual Meeting MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that multiple abstracts from the Company's tafasitamab program have been accepted for oral and poster presentations at the upcoming 2020 American Society of Clinical Oncology (ASCO) Virtual Meeting, May 29 - May 31, 2020 and at the virtual 25th Congress of the European Hematology Association (EHA25 Virtual), June 11-14, 2020. Tafasitamab is MorphoSys' investigational anti-CD19 antibody, currently under priority review by the FDA in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). "We are excited to provide a number of important updates on tafasitamab in this new virtual setting," commented Dr. Malte Peters, Chief Research and Development Officer of MorphoSys. "The data we and our partners will present highlight our progress towards making novel therapies available to eligible patients in need as soon as possible." MorphoSys will meet registered ASCO20 Virtual and EHA25 Virtual attendees at its virtual booths accessible through the conference websites. Key abstracts accepted for presentation at ASCO20 Virtual and EHA25 Virtual include: ASCO20 VirtualE-Poster PresentationRE-MIND STUDY: A PROPENSITY SCORE-BASED 1:1 MATCHED COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VERSUS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)Abstract/Poster No.: 8020/353 Session: Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia Presentation Time: Friday, May 29, 2020, 8:00 AM EDT EHA25 VirtualOral PresentationRE-MIND STUDY: COMPARISON OF TAFASITAMAB + LENALIDOMIDE (L-MIND) VS LENALIDOMIDE MONOTHERAPY (REAL-WORLD DATA) IN TRANSPLANT-INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAAbstract No.: S238 Session: 19. Aggressive Non-Hodgkin lymphoma - Clinical Presentation Time: Friday, June 12, 8:30 CEST E-Poster Presentations:LONG-TERM OUTCOMES FROM THE PHASE II L-MIND STUDY OF TAFASITAMAB (MOR208) PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAAbstract No.: EP1201 Session: 19. Aggressive Non-Hodgkin lymphoma - Clinical Presentation Time: Friday, June 12, 8:30 CEST EXPRESSION OF CD19 ANTIGEN ON CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AFTER TAFASITAMAB (ANTI-CD19) TREATMENT: PHASE I TRIAL DATAAbstract No.: EP671 Session: 05. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research Presentation Time: Friday, June 12, 8:30 CEST COMBINATION OF TAFASITAMAB (MOR208) AND LENALIDOMIDE ENHANCES TUMOR CELL DEATH OF B-CELL LYMPHOMA IN VITRO Abstract No.: EP1343 Session: 20. Lymphoma Biology & Translational Research Presentation Time: Friday, June 12, 8:30 CEST Please refer to the ASCO20 Virtual (https://meetinglibrary.asco.org) and EHA25 Virtual (https://learningcenter.ehaweb.org/eha) online programs for full session details and data presentation listings. About tafasitamab Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. In January 2020, MorphoSys and Incyte Corporation entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. If approved in the U.S., MorphoSys and Incyte will co-commercialize tafasitamab; Incyte will have exclusive commercialization rights outside the U.S. Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials, including L-MIND and Re-MIND. Additionally, tafasitamab is being evaluated as part of the ongoing Phase 3 study B-MIND study assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. Tafasitamab is also currently being investigated in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has over 400 employees. More information at www.morphosys.com.HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc. MorphoSys forward-looking statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreements for tafasitamab, the further clinical development of Tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact: MorphoSysInvestor Contact: Dr. Julia Neugebauer Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-179 Julia.Neugebauer@morphosys.com Media Contacts: Dr. Anca Alexandru Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26738 Anca.Alexandru@morphosys.com Dr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 Verena.Kupas@morphosys.com * * *Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=NOKEQJDYUT Document title: Media Release * * *14.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1045629 End of News DGAP News Service
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 14.05.2020 / 15:25 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Wilmington, Delaware, U.S., May 14, 2020 MorphoSys and Incyte Announce Long-term Follow-up Results from L-MIND Study of Tafasitamab in Patients with r/r DLBCL * New two-year follow-up data (November 30, 2019 cut-off) of L-MIND trial corroborate previously reported primary analysis * Updated IRC efficacy outcomes include objective response rate (ORR) of 58.8%, complete response (CR) rate of 41.3% * Median duration of response (mDOR) of 34.6 months, median progression-free survival (mPFS) of 16.2 months, and median overall survival (mOS) of 31.6 months * Full efficacy and safety data to be presented virtually at the 25th EHA Annual Congress MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today reported updated results from the ongoing Phase 2 L-MIND study investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The results, based on a November 30, 2019 data cut-off, corroborate previously reported primary analysis data. In this long-term analysis of the L-MIND data, 80 study patients receiving tafasitamab plus lenalidomide were included in the efficacy analysis. After a minimum of two years' follow-up, outcomes from the L-MIND study are consistent with the primary analysis and confirm the durability of the response (DoR) and overall survival (OS) of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in autologous stem cell transplantation (ASCT)-ineligible patients with r/r DLBCL. Assessment by an independent review committee (IRC) at data cut-off showed an objective response rate (ORR) of 58.8% (47 out of 80 patients) and a complete response (CR) rate of 41.3% (33 out of 80 patients). Median duration of response (mDOR) was 34.6 months, with median overall survival (mOS) of 31.6 months and median progression-free survival (mPFS) of 16.2 months. The safety profile was consistent with that observed in previously reported studies of tafasitamab in combination with lenalidomide. The full analysis will be presented virtually at the 25th EHA Annual Congress to be held June 11-14, 2020. "We are extremely encouraged by the long-term data from our L-MIND study which confirms the previously reported results from the primary analysis," commented Dr. Malte Peters, Chief Research and Development Officer, MorphoSys. "Tafasitamab in combination with lenalidomide has the potential to address the significant medical need in patients suffering from r/r DLBCL, and we are working diligently towards our key priority of making tafasitamab available to eligible patients." "The updated data for L-MIND reinforce the potential of tafasitamab in combination with lenalidomide as treatment for patients with r/r DLBCL. We look forward to working with our partners at MorphoSys as we seek to bring this new therapeutic option to eligible patients globally," Peter Langmuir, M.D., Group Vice President, Oncology Targeted Therapeutics, Incyte. A Biologics License Application (BLA) for tafasitamab in combination with lenalidomide for r/r DLBCL is currently under Priority Review by the U.S. Food and Drug Administration (FDA) (PDUFA action date August 30, 2020). The BLA is based on data including the primary analysis of L-MIND with a previous cut-off date as of November 30, 2018, and the primary analysis data from the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy. In January 2020, MorphoSys and Incyte Corporation entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. If approved, MorphoSys and Incyte will co-commercialize tafasitamab in the United States while Incyte has exclusive commercialization rights outside the United States. About L-MIND L-MIND is a single arm, open-label Phase 2 study, investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Primary analysis data with a cut-off date of November 30, 2018 included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update were based on response rates assessed by an independent review committee for all 80 patients. About Re-MIND Re-MIND, an observational retrospective study, was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory DLBCL who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys' L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy. About tafasitamab Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb(R) engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. In January 2020, MorphoSys and Incyte Corporation entered into a collaboration and licensing agreement to further develop and commercialize tafasitamab globally. If approved in the U.S., MorphoSys and Incyte will co-commercialize tafasitamab; Incyte will have exclusive commercialization rights outside the U.S. Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in a number of ongoing combination trials, including L-MIND and Re-MIND. Additionally, tafasitamab is being evaluated as part of the ongoing Phase 3 study B-MIND study assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. Tafasitamab is also currently being investigated in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has over 400 employees. More information at www.morphosys.com.HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc. About Incyte Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte. MorphoSys forward-looking statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreements for tafasitamab, the further clinical development of Tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab including the L-MIND and Re-MIND studies, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. Incyte forward-looking statements Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether tafasitamab will be approved for use in humans anywhere in Europe, the U.S. or elsewhere or will be commercialized in Europe, the U.S. or elsewhere successfully or at all; whether tafasitamab will be effective in the treatment of the indications discussed in this press release; and the expectations, timing and potential results of further development activities involving tafasitamab. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining regulatory approval for this planned collaboration; research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors, including other scientific developments; unanticipated delays; the effects of market competition; risks associated with relationships between collaboration partners; the impact of governmental actions regarding pricing, importation and reimbursement for pharmaceuticals; and such other risks detailed from time to time in each company's reports filed with the Securities and Exchange Commission, including Incyte's annual report on Form 10-Q for the quarter ending March 31, 2020 and MorphoSys' Annual Report on Form 20-F for the fiscal year ended December 31, 2019 Each party disclaims any intent or obligation to update these forward-looking statements. For more information, please contact: MorphoSysInvestor Contact: Dr. Julia Neugebauer Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-179 Julia.Neugebauer@morphosys.com Media Contacts: Dr. Anca Alexandru Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26738 Anca.Alexandru@morphosys.com Dr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 Verena.Kupas@morphosys.com Incyte Investor Contact: Dr. Michael Booth Division Vice President, Investor Relations & Corporate Responsibility Tel: +1 302 498 5914 mbooth@incyte.com Media Contacts: Catalina Loveman Executive Director, Public Affairs Tel: +1 302 498 6171 cloveman@incyte.com Ela Zawislak Director, Public Affairs Tel: + 41 21 343 3113 ezawislak@incyte.com * * *Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=PBUTMMFYSA Document title: Media Release * * *14.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1044955 End of News DGAP News Service
MorphoSys AG 07.05.2020 / 17:00 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1\. Details of issuer Name: MorphoSys AG Street: Semmelweisstr. 7 Postal code: 82152 City: Planegg Germany Legal Entity Identifier (LEI): 529900493806K77LRE72 2\. Reason for notification X Acquisition/disposal of shares with voting rights Acquisition/disposal of instruments Change of breakdown of voting rights X Other reason: voluntary group notification due to crossing a threshold on subsidiary level 3\. Details of person subject to the notification obligation Legal entity: BlackRock, Inc. City of registered office, country: Wilmington, Delaware, United States of America (USA) 4\. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5\. Date on which threshold was crossed or reached: 29 Apr 2020 6\. Total positions % of voting rights attached to shares (total of 7.a.) % of voting rights through instruments (total of 7.b.1 + 7.b.2) Total of both in % (7.a. + 7.b.) Total number of voting rights pursuant to Sec. 41 WpHG New 6.93 % 0.63 % 7.56 % 32890046 Previous notification 7.22 % 0.66 % 7.88 % / 7\. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN Absolute In % Direct (Sec. 33 WpHG) Indirect (Sec. 34 WpHG) Direct (Sec. 33 WpHG) Indirect (Sec. 34 WpHG) DE0006632003 0 2151887 0 % 6.54 % US6177602025 0 128512 0 % 0.39 % Total 2280399 6.93 % b.1. Instruments according to Sec. 38 (1) no. 1 WpHG Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in % Lent Securities (right to recall) N/A N/A 206242 0.63 % Total 206242 0.63 % b.2. Instruments according to Sec. 38 (1) no. 2 WpHG Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in % Contract for Difference N/A N/A Cash 216 0.001 % Total 216 0.001 % 8\. Information in relation to the person subject to the notification obligation Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.). X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity: Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more) BlackRock, Inc. % % % Trident Merger LLC % % % BlackRock Investment Management, LLC % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock Capital Holdings, Inc. % % % BlackRock Advisors, LLC % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock (Singapore) Holdco Pte. Ltd. % % % BlackRock (Singapore) Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock Holdco 4, LLC % % % BlackRock Holdco 6, LLC % % % BlackRock Delaware Holdings Inc. % % % BlackRock Fund Advisors % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock Holdco 4, LLC % % % BlackRock Holdco 6, LLC % % % BlackRock Delaware Holdings Inc. % % % BlackRock Institutional Trust Company, National Association % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Australia Holdco Pty. Ltd. % % % BlackRock Investment Management (Australia) Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Canada Holdings LP % % % BlackRock Canada Holdings ULC % % % BlackRock Asset Management Canada Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock International Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock (Netherlands) B.V. % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock Advisors (UK) Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Luxembourg Holdco S.a.r.l. % % % BlackRock (Luxembourg) S.A. % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock Investment Management (UK) Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Luxembourg Holdco S.a.r.l. % % % BlackRock Investment Management Ireland Holdings Limited % % % BlackRock Asset Management Ireland Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Luxembourg Holdco S.a.r.l. % % % BlackRock UK Holdco Limited % % % BlackRock Asset Management Schweiz AG % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock Investment Management (UK) Limited % % % BlackRock Fund Managers Limited % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock Investment Management (UK) Limited % % % BlackRock Asset Management Deutschland AG % % % - % % % BlackRock, Inc. % % % BlackRock Holdco 2, Inc. % % % BlackRock Financial Management, Inc. % % % BlackRock International Holdings, Inc. % % % BR Jersey International Holdings L.P. % % % BlackRock Holdco 3, LLC % % % BlackRock Cayman 1 LP % % % BlackRock Cayman West Bay Finco Limited % % % BlackRock Cayman West Bay IV Limited % % % BlackRock Group Limited % % % BlackRock Finance Europe Limited % % % BlackRock Investment Management (UK) Limited % % % BlackRock Asset Management Deutschland AG % % % iShares (DE) I Investmentaktiengesellschaft mit Teilgesellschaftsvermögen % % % - % % % 9\. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting: Proportion of voting rights Proportion of instruments Total of both % % % 10\. Other explanatory remarks: Date 05 May 2020 * * *07.05.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Internet: www.morphosys.com End of News DGAP News Service
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous 30.04.2020 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, April 30, 2020Invitation to MorphoSys' First Quarter 2020 Results Conference Call on May 7, 2020 MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its results for the first quarter of 2020 on May 6, 2020 at 10:00pm CEST (9:00pm BST; 4:00pm EDT).MorphoSys' Management team will host a conference call and webcast on May 7, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys' results for the first quarter and provide a financial and operational outlook for 2020. Date of the conference call: Thursday, May 7, 2020 Time: 2:00pm CEST (1:00pm BST, 8:00am EDT) Dial-in numbers: Germany: +49 69 201 744 220 United Kingdom: +44 203 009 2470 USA: +1 877 423 0830 (all numbers reachable from any geography) Participant PIN: 14809293 Participants are kindly requested to dial in up to 10 minutes before the call to ensure a secure line and a prompt start.The presentation slides and webcast link will be available at the Company's website at http://www.morphosys.com/conference-callsA replay of the conference will also be available at the corporate website following the live event. About MorphoSys MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has over 400 employees. More information at www.morphosys.com HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc. XmAb(R) is a trademark of Xencor, Inc. MorphoSys forward looking statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the licensing agreements for tafasitamab, the further clinical development of tafasitamab, interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab as well as the potential future commercialization of tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. For more information, please contact:MorphoSysInvestor Contact: Dr. Julia Neugebauer Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-179 Julia.Neugebauer@morphosys.com Media Contacts: Dr. Anca Alexandru Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26738 Anca.Alexandru@morphosys.com Dr. Verena Kupas Associate Director Corporate Communications & IR Tel: +49 (0) 89 / 899 27-26814 Verena.Kupas@morphosys.com * * *Additional features: Document: https://eqs-cockpit.com/c/fncls.ssp?u=EQSQHSIBKN Document title: Conference Call * * *30.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de * * * Language: English Company: MorphoSys AG Semmelweisstr. 7 82152 Planegg Germany Phone: +49 (0)89 899 27-0 Fax: +49 (0)89 899 27-222 E-mail: investors@morphosys.com Internet: www.morphosys.com ISIN: DE0006632003 WKN: 663200 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq EQS News ID: 1034215 End of News DGAP News Service